The Seeker requests novel biomarkers of response to the anti-angiogenic biologic therapy Bevacizumab. For this Theoretical Challenge, Solvers should provide pen and paper solutions describing their ideas for a biomarker.
The primary interest of the Seeker is to either predict or identify patients who derive limited benefit from therapy with the anti-angiogenic monoclonal antibody bevacizumab or to predict which groups of patients are deriving more substantial benefit from this therapy. This Challenge focuses on gaining insights from the population of physicians, caregivers, researchers and patients who may have proposals for novel biomarkers. As a Theoretical Challenge, only a written proposal is required. More details are available within the Challenge details.
What is a Theoretical-Licensing Challenge?
An InnoCentive Theoretical Challenge builds upon an idea but is not yet a proof of concept. A solution to a Theoretical Challenge will solidify the Solver's concept with detailed descriptions, specifications and requirements necessary to bringing a good idea closer to becoming an actual product or service.
This Challenge is a Theoretical-Licensing Challenge, meaning that the Seeker is requesting non-exclusive rights to use the winning solution. By contrast, Theoretical-IP Transfer means that Solvers must relinquish all rights to the Intellectual Property (IP) for which they are awarded. For these forms of a Theoretical Challenge, Solvers that do not win retain the rights to their solution after the evaluation period is complete. The Seeker retains no rights to any IP not awarded.